Introduction:
Hypertrophic cardiomyopathy (HCM) is an underrecognized cause of heart failure, arrhythmias, and sudden cardiac death in older adults, where distinguishing HCM from age-related or hypertensive left ventricular hypertrophy (LVH) remains challenging. Early identification is critical but often delayed due...
M. Juneja, H. Ramteke, Valency Pateliya et al.· Circulation· 0 citations
Introduction:
Reanalysis of the Women's Health Initiative has renewed debate on menopause hormone therapy (MHT) and cardiovascular risk. Whether MHT's cardiometabolic effects differ by formulation, route, or timing of initiation in women with or at risk for cardiovascular disease (CVD) remains unclear. This meta-ana...
Clarke Setrice Patricia, Daniel Mwesigwa Kiyimba, H. Ramteke et al.· Circulation· 0 citations
Introduction:
Resistant hypertension often persists despite multidrug therapy, driven by unopposed aldosterone activity. In May 2026, the FDA approved baxdrostat, a first-in-class aldosterone synthase inhibitor. Other agents include mineralocorticoid receptor antagonists (MRAs) such as spironolactone and eplerenone....
R. Khan, H. Ramteke, Sai Sravanth Reddy Tamma et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.